Although the FDA approval of the 2 kinase inhibitors, lenvatinib (Lenvima) and sorafenib (Nexavar), has improved progression-free survival (PFS) rates, the responses to treatment with these agents are not durable and more treatments are needed.


Results 1 - 1 of 1